A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single Agent Maintenance
Protocol: SWOG – S2209 SCHEMA S2209 Please Note: Below is a brief list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038, to discuss the full list of eligibility. Eligibility: Participants must have documented multiple myeloma satisfying standard International Myeloma Working Group (IMWG). Participants must have measurable disease. […]
Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult Survivors of Hodgkin and Non-Hodgkin Lymphoma
Protocol: ECOG – EAQ211 SCHEMA EAQ211 Please Note: Below is a brief description of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079, or (810)762-8038 to discuss full eligibility requirements Eligibility: Patient must be ≥ 18 years of age at the time of registration. Patient must have been between the ages […]
A Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma
Protocol: SWOG – S2207 SCHEMA S2207 Please Note: Below is a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038 to discuss complete eligibility requirements. Thank you! Eligibility: Histologically confirmed relapsed/refractory LBCL as outlined by the World Health Organization (WHO) guidelines, classified as one of the […]
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Protocol: ECOG – EA9181 SCHEMA EA9181 Please Note: Below is a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss the full list of eligibility. Thank you! Eligibility: Patient must be ≥ 18 and ≤ 75 years of age. Patient must […]
Randomized Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Protocol: SWOG – S1925 SCHEMA S1925 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Participants must have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants must have CLL-International Prognostic Index (CLL-IPI) […]